LOGIN
Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases
October 2020
Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials.
J Am Acad Orthop Surg Glob Res Rev. 2020 Aug; 4(8): e20.00045.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Four studies including 7320 patients with bone metastases from advanced cancer were included in this meta-analysis comparing the likelihood of pathological fracture. Sub-group analyses were performed by tumour origin (endodermal cancer, mesodermal cancer). Pooled results found the likelihood of pathological fracture to be significantly lower in the denosumab group compared to the zoledronic acid g...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.